3D Microfluidic Eye Model for Outer Blood-Retinal Barrier Mimicry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro models fail to realistically mimic the retinal pigment epithelium (RPE)-choroid complex, a crucial tissue-tissue interface in the human retina, limiting studies on age-related macular degeneration (AMD) and drug discovery.
Innovation Solution
A three-dimensional microfluidic chip system is developed, incorporating retinal pigment epithelial cells derived from induced pluripotent stem cells, perfusable vessels, and an extracellular matrix hydrogel, to create a realistic model of the outer blood-retinal barrier (oBRB) that mimics the anatomical and physiological features of the human retina.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional in vitro models are used, then simplicity and ease of operation are maintained, but the ability to realistically mimic the RPE-choroid complex and tissue-tissue interface is insufficient
Solution Approach 1:
The patent implements a nested structure where the RPE cell layer is positioned within a three-dimensional extracellular matrix hydrogel, which itself is embedded in a microfluidic device. This nested arrangement allows the complex tissue interface to be contained within a manageable device framework, achieving realistic tissue mimicry without proportionally increasing operational complexity
Solution Approach 2:
The patent transitions from traditional two-dimensional cell culture to a three-dimensional organoid model. The RPE cells are cultured within a 3D extracellular matrix hydrogel structure, enabling realistic tissue architecture and cell-cell interactions while the microfluidic system manages the complexity through standardized fluid handling interfaces
2Reliability
If rodent models are used for AMD studies, then availability and ease of manufacture are improved, but the ability to fully mimic human AMD characteristics is limited due to lack of macula
Solution Approach 1:
The patent creates an in vitro copy of the human RPE-choroid complex that replicates key anatomical and physiological features without requiring whole animal models. The three-dimensional organoid system copies the essential tissue architecture and cellular interactions, providing human-relevant AMD pathology studies while avoiding the anatomical limitations of rodent models
Solution Approach 2:
The microfluidic device platform serves multiple functions: it provides structural support for the 3D organoid, enables controlled nutrient and drug delivery through perfusable channels, and allows for various assay types. This universal platform can model different pathological conditions and test multiple therapeutic agents using the same basic system, improving ease of manufacture and availability
3Manufacturing precision
If simple in vitro models are used, then ease of operation is maintained, but the ability to model the tissue-tissue interface and provide realistic anatomical structure is insufficient
Solution Approach 1:
The extracellular matrix hydrogel is pre-formed with appropriate three-dimensional structure and cell encapsulation before being integrated into the microfluidic device. This preliminary preparation of the tissue structure allows the device to be assembled in a standardized manner, maintaining ease of operation while achieving precise anatomical organization
Solution Approach 2:
The extracellular matrix hydrogel acts as a flexible, three-dimensional scaffold that can be molded into the desired anatomical shape and then integrated into the rigid microfluidic device. This combination of flexible tissue structure with a rigid operational platform achieves manufacturing precision while preserving ease of operation through modular assembly
Data Source
AI summary
This present disclosure relates to a bioengineering approach based on microphysiological culture to mimic tissue-tissue interface. Accordingly, the present disclosure provides methods, compositions and kits related to the approach.